Who are Aspirin, acetaminophen and caffeine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Combined Acetaminophen and Ibuprofen, Analgesic/antipyretic and antihistamine drugs.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/aspirin-acetaminophen-and-caffeine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Aspirin, acetaminophen and caffeine — Competitive Intelligence Brief

Aspirin, acetaminophen and caffeine (Aspirin, acetaminophen and caffeine) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination analgesic/antipyretic. Area: Pain Management.

marketed Combination analgesic/antipyretic Pain Management Small molecule Live · refreshed every 30 min

Target snapshot

Aspirin, acetaminophen and caffeine (Aspirin, acetaminophen and caffeine) — Novartis. This combination analgesic and antipyretic works through multiple pathways: aspirin inhibits cyclooxygenase to reduce prostaglandins, acetaminophen inhibits pain and fever centers in the CNS, and caffeine enhances analgesic efficacy while promoting alertness.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Aspirin, acetaminophen and caffeine TARGET	Aspirin, acetaminophen and caffeine	Novartis	marketed	Combination analgesic/antipyretic
Combined Acetaminophen and Ibuprofen	Combined Acetaminophen and Ibuprofen	Washington University School of Medicine	phase 3	Fixed-dose combination analgesic/antipyretic	COX-1, COX-2 (ibuprofen component); unclear central target (acetaminophen component)
Analgesic/antipyretic and antihistamine drugs	Analgesic/antipyretic and antihistamine drugs	Genentech, Inc.	phase 3	Combination analgesic/antipyretic and antihistamine

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination analgesic/antipyretic class)

Novartis · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Aspirin, acetaminophen and caffeine — Competitive Intelligence Brief. https://druglandscape.com/ci/aspirin-acetaminophen-and-caffeine. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab